Longitudinal Changes in Cholesterol Efflux Capacities in Patients With Coronary Artery Disease Undergoing Lifestyle Modification Therapy. Issue 11 (29 September 0207)

• Record Type: Journal Article
• Authors: Boyer, Marjorie; Lévesque, Valérie; Poirier, Paul; Marette, André; Mitchell, Patricia L.; Mora, Samia; Mathieu, Patrick; Després, Jean‐Pierre; Larose, Éric; Arsenault, Benoit J.
• Is Part Of: Journal of the American Heart Association. Volume 7:Issue 11(2018)
• Page Start: n/a
• Page End: n/a
• Publication Date: 0207-09-29
• Subjects: adipose tissue -- cholestrol efflux capacity -- coronary artery disease -- lifestyle -- lipids and lipoproteins; Heart -- Diseases -- Periodicals; Cardiovascular system -- Diseases -- Periodicals; Cerebrovascular disease -- Periodicals; Cardiology -- Periodicals; 616.1
• DOI: 10.1161/JAHA.118.008681
• Languages: English
• ISSNs: 2047-9980

Abstract

Abstract : Background: Our objective was to identify the determinants of high‐density lipoprotein cholesterol efflux capacity (HDL‐CEC) changes in patients with coronary artery disease who participated in a lifestyle modification program aimed at increasing physical activity levels and improving diet quality. Methods and Results: A total of 86 men with coronary artery disease aged between 35 and 80 years participated in a 1‐year lifestyle modification program that aimed to achieve a minimum of 150 minutes of aerobic physical activity weekly and improve diet quality. HDL‐CECs were measured before and after the 1‐year intervention using 3 H‐cholesterol–labeled J774 and HepG2 cells. Visceral, subcutaneous, and cardiac adipose tissue levels were assessed before and after the intervention using magnetic resonance imaging. Lipoprotein particle size and concentrations were measured by proton nuclear magnetic resonance spectroscopy and a complete lipoprotein‐lipid profile was obtained. At baseline, the best correlate of HDL‐CECs were apolipoprotein AI ( R 2 =0.35, P <0.0001) and high‐density lipoprotein cholesterol ( R 2 =0.21, P <0.0001) for J774‐HDL‐CECs and HepG2‐HDL‐CECs, respectively. Baseline and longitudinal changes in HDL‐CECs were associated with several lipoprotein size and concentration indices, although high‐density lipoprotein cholesterol was the best predictor of longitudinal changes in J774‐HDL‐CECs ( R 2 =0.18, P =0.002) and apolipoprotein AI was found to be the best predictor of longitudinal changes in HepG2 cholesterol efflux capacities ( R 2 =0.21, P =0.002). Conclusions: Results of this study suggest that increases in high‐density lipoprotein cholesterol and apolipoprotein AI levels typically observed in patients with coronary artery disease undergoing healthy lifestyle modification therapy may be indicative of higher plasma concentrations of functional high‐density lipoprotein particles.